A Phase 2 interventional study of LME636 60 mg/mL ophthalmic solution and Dexamethasone 0.1% ophthalmic solution in Acute Anterior Uveitis, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-02.
Sponsored by Alcon Research (part of Alcon) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to determine whether topical ocular administration of LME636 60 mg/mL is efficacious in resolving the ocular inflammation in the anterior chamber (AC) associated with acute anterior uveitis (AAU).
Eligible subjects will be randomized to LME636 or Dexamethasone in a 3:1 ratio at the time they present to the trial site with the AAU flare and will enter treatment for 28 full days. Subjects with worsening disease from Visit 2/Day 4 onward or subjects without improvement after 14 days of treatment will be discontinued from treatment, unmasked and treated with a rescue regimen at the discretion of the investigator.
56 studies on the registry are indexed under Uveitis, Anterior; 9 are open to participants now.
This study's enrollment of 45 is close to the median of 50 across 45 interventional studies indexed under Uveitis, Anterior.
Browse Uveitis, Anterior studies →Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LME636 60 mg/mL ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 1 week (Week 3) and 1 week of masked Vehicle administration (Week 4)
Drug: LME636 60 mg/mL ophthalmic solution · Drug: LME636 Vehicle
Dexamethasone 0.1% ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 2 weeks (Weeks 3 and 4)
Drug: Dexamethasone 0.1% ophthalmic solution
Drug page: Licaminlimab
Inactive ingredients used for masking purposes
Number of Responders at Day 15
Response was defined as a two-step decrease or more from baseline in Anterior Chamber (AC) Cell Grade as per Standardization of Uveitis Nomenclature (SUN). Baseline was defined as the measurement taken before drug administration on Day 1. Subjects receiving rescue treatment on or before Day 15 were considered non-responders. Only one eye contributed to the analysis.
Time frame: Baseline (Day 1), Day 15
Mean Best Corrected Visual Acuity (BCVA) at Each Visit
Visual Acuity (VA) with the subject's best spectacles or other visual corrective devices was measured using an Early Treatment of Diabetic Retinopathy Study (ETDRS) or Snellen visual acuity chart and reported in letters read correctly. An increase (gain) in letters read indicates improvement. Only one eye contributed to the analysis.
Time frame: Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29
Mean Intraocular Pressure (IOP) at Each Visit
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry or Tonopen and reported in millimeters mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Only one eye contributed to the analysis.
Time frame: Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29
Number of Subjects With Increase From Baseline in Slit Lamp Parameters at Any Post-Treatment Visit
Slit-lamp biomicroscopy (examination) was performed to evaluate the anterior segment of the eye, including lids/lashes, conjunctiva, cornea, anterior chamber (cells and flare), iris, and lens. Ocular signs were categorized as Aqueous Flare, Aqueous Inflammatory Cell Grade, Keratic Precipitates, Lens, Limbal Injection, Status of Lens, Peripheral Anterior Synechia, and Posterior Synechia. An increase indicates worsening. Only one eye contributed to the analysis.
Time frame: Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29
Number of Subjects With an Increase From Baseline in Dilated Fundus Parameters at Any Post-Treatment Visit
The dilated fundus examination was performed to evaluate the health of the vitreous, optic disc, retinal vessels, macula, and retinal periphery. An increase indicates worsening. Only one eye contributed to the analysis.
Time frame: Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29
Number of Subjects With IOP Change From Baseline to Last On-Treatment Assessment
IOP was assessed using Goldmann applanation tonometry or Tonopen and reported in mmHg. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Only one eye contributed to the analysis.
Time frame: Baseline (Day 1), Up to Day 29
Mean Change From Baseline in BCVA at Each Visit
Visual Acuity (VA) was measured with the participant's best spectacles or other visual corrective device in place using an ETDRS or Snellen visual acuity chart. Improvement of BCVA was defined as an increase (gain) in letters read from the baseline assessment. Only one eye contributed to the analysis.
Time frame: Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29
Time-to-Response
Time-to-Response was defined as the number of days from baseline to the first scheduled visit when a two-step decrease or more from baseline in AC Cell Grade (as per SUN) was observed. Time-to-Response is reported as number of subjects presenting time-to-response by visit. Only one eye contributed to the analysis.
Time frame: Baseline (Day 1), Up to Day 15
Use of Rescue Treatment
Use of rescue treatment is presented as the number of subjects with first use of rescue treatment by visit. Subjects receiving rescue medication were not considered withdrawn and the collection of data continued after discontinuation of study treatment. Only one eye contributed to the analysis.
Time frame: Day 4, Day 8, Day 15
Mean Serum Concentration of Total LME636 at Each Visit
Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. Concentrations below the limit of quantification (BLQ), defined as 0.25 ng/mL, were reported as NA with no imputation for missing data.
Time frame: Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29
Number of Subjects With Anti-LME636 Antibodies Present at Each Visit
Serum samples were collected and assessed for anti-LME636 antibodies. Samples collected from subjects in the LME636 dose group were analyzed for anti-LME636 antibodies. For subjects in the dexamethasone group, only the samples collected on Day 1 (ie, prior to the start of treatment) were analyzed for anti-LME636 antibodies.
Time frame: Day 1, Day 4, Day 8, Day 15, Day 22, Day 29
Subjects were recruited from 10 study centers located in the United States.
| Milestone | LME636 | Dexamethasone |
|---|---|---|
| Started | 32 | 11 |
| Treated, as randomized | 30 | 9 |
| Completed | 26 | 9 |
| Not completed | 6 | 2 |
| Withdrew: Adverse event-prior to treatment | 0 | 1 |
| Withdrew: Withdrawal by subject-prior to treatment | 0 | 1 |
| Withdrew: Unable to draw blood-prior to treatment | 1 | 0 |
| Withdrew: Criteria not met-prior to treatment | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Criteria not met | 1 | 0 |
Response was defined as a two-step decrease or more from baseline in Anterior Chamber (AC) Cell Grade as per Standardization of Uveitis Nomenclature (SUN). Baseline was defined as the measurement taken before drug administration on Day 1. Subjects receiving rescue treatment on or before Day 15 were considered non-responders. Only one eye contributed to the analysis.
| Participants | LME636 | Dexamethasone |
|---|---|---|
| Number of Responders at Day 15 | 14 | 9 |
Visual Acuity (VA) with the subject's best spectacles or other visual corrective devices was measured using an Early Treatment of Diabetic Retinopathy Study (ETDRS) or Snellen visual acuity chart and reported in letters read correctly. An increase (gain) in letters read indicates improvement. Only one eye contributed to the analysis.
| letters | LME636 | Dexamethasone |
|---|---|---|
| Baseline | 71.1 ± 14.58 | 77.2 ± 14.69 |
| Day 4 | 70.5 ± 13.92 | 77.9 ± 12.94 |
| Day 8 | 72.1 ± 13.62 | 76.8 ± 11.50 |
| Day 15 | 74.1 ± 10.11 | 77.1 ± 11.82 |
| Day 22 | 74.5 ± 10.41 | 78.2 ± 11.31 |
| Day 29 | 73.8 ± 11.70 | 79.2 ± 11.23 |
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry or Tonopen and reported in millimeters mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Only one eye contributed to the analysis.
| mmHg | LME636 | Dexamethasone |
|---|---|---|
| Baseline (Day 1) | 15.2 ± 5.09 | 15.5 ± 4.12 |
| Day 4 | 14.8 ± 3.74 | 15.3 ± 3.47 |
| Day 8 | 14.1 ± 3.40 | 16.1 ± 3.51 |
| Day 15 | 14.0 ± 3.38 | 16.0 ± 5.06 |
| Day 22 | 14.6 ± 3.14 | 17.0 ± 4.57 |
| Day 29 | 15.5 ± 4.72 | 16.3 ± 4.40 |
Slit-lamp biomicroscopy (examination) was performed to evaluate the anterior segment of the eye, including lids/lashes, conjunctiva, cornea, anterior chamber (cells and flare), iris, and lens. Ocular signs were categorized as Aqueous Flare, Aqueous Inflammatory Cell Grade, Keratic Precipitates, Lens, Limbal Injection, Status of Lens, Peripheral Anterior Synechia, and Posterior Synechia. An increase indicates worsening. Only one eye contributed to the analysis.
| participants | LME636 | Dexamethasone |
|---|---|---|
| Aqueous Flare | 9 | 1 |
| Aqueous Inflammatory Cell Grade | 4 | 1 |
| Keratic Precipitates | 4 | 0 |
| Lens | 0 | 0 |
| Limbal Injection | 7 | 0 |
| Status of Lens | 0 | 0 |
| Peripheral Anterior Synechia | 1 | 1 |
| Posterior Synechiae | 8 | 1 |
The dilated fundus examination was performed to evaluate the health of the vitreous, optic disc, retinal vessels, macula, and retinal periphery. An increase indicates worsening. Only one eye contributed to the analysis.
| participants | LME636 | Dexamethasone |
|---|---|---|
| Macula | 2 | 0 |
| Optic Nerve | 1 | 0 |
| Retina | 1 | 0 |
| Vitreous | 4 | 0 |
IOP was assessed using Goldmann applanation tonometry or Tonopen and reported in mmHg. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Only one eye contributed to the analysis.
| Participants | LME636 | Dexamethasone |
|---|---|---|
| Increase > 30 mmHg | 0 | 0 |
| Increase 11-30 mmHg | 1 | 0 |
| Increase 6-10 mmHg | 0 | 2 |
| -5 mmHg Decrease - 5 mmHg Increase | 25 | 8 |
| Decrease 6-10 mmHg | 1 | 0 |
| Decrease 11-30 mmHg | 2 | 0 |
| Decrease > 30 mmHg | 0 | 0 |
Visual Acuity (VA) was measured with the participant's best spectacles or other visual corrective device in place using an ETDRS or Snellen visual acuity chart. Improvement of BCVA was defined as an increase (gain) in letters read from the baseline assessment. Only one eye contributed to the analysis.
| letters | LME636 | Dexamethasone |
|---|---|---|
| Baseline (BL) | 71.1 ± 14.58 | 77.2 ± 14.69 |
| Change from BL at Day 4 | -0.1 ± 9.74 | 0.7 ± 5.40 |
| Change from BL at Day 8 | 0.0 ± 12.84 | -0.4 ± 6.19 |
| Change from BL at Day 15 | 2.1 ± 9.53 | -0.1 ± 3.73 |
| Change from BL at Day 22 | 2.8 ± 9.10 | 1.0 ± 5.06 |
| Change from BL at Day 29 | 2.1 ± 10.36 | 2.0 ± 5.37 |
Time-to-Response was defined as the number of days from baseline to the first scheduled visit when a two-step decrease or more from baseline in AC Cell Grade (as per SUN) was observed. Time-to-Response is reported as number of subjects presenting time-to-response by visit. Only one eye contributed to the analysis.
| Participants | LME636 | Dexamethasone |
|---|---|---|
| Day 4 | 9 | 7 |
| Day 8 | 5 | 2 |
| Day 15 | 1 | 0 |
| Non-Responder | 10 | 1 |
Use of rescue treatment is presented as the number of subjects with first use of rescue treatment by visit. Subjects receiving rescue medication were not considered withdrawn and the collection of data continued after discontinuation of study treatment. Only one eye contributed to the analysis.
| Participants | LME636 | Dexamethasone |
|---|---|---|
| Day 4 | 3 | 0 |
| Day 8 | 3 | 0 |
| Day 15 | 0 | 0 |
| No Rescue | 19 | 10 |
Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. Concentrations below the limit of quantification (BLQ), defined as 0.25 ng/mL, were reported as NA with no imputation for missing data.
| ng/mL | LME636 |
|---|---|
| Day 1 | NA ± NA |
| Day 4 | NA ± NA |
| Day 8 | NA ± NA |
| Day 15 | NA ± NA |
| Day 22 | 0.2510 ± 0.31237 |
| Day 29 | NA ± NA |
Serum samples were collected and assessed for anti-LME636 antibodies. Samples collected from subjects in the LME636 dose group were analyzed for anti-LME636 antibodies. For subjects in the dexamethasone group, only the samples collected on Day 1 (ie, prior to the start of treatment) were analyzed for anti-LME636 antibodies.
| Participants | LME636 | Dexamethasone |
|---|---|---|
| Day 1 | 5 | 3 |
| Day 4 | 5 | — |
| Day 8 | 6 | — |
| Day 15 | 11 | — |
| Day 22 | 17 | — |
| Day 29 | 18 | — |
Collected over Adverse events (AEs) were collected from time of consent for the duration of a subject's participation in the study (up to 35 days). AEs are reported as pretreatment, treatment-emergent, and posttreatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pretreatment | 0/45 (0%) | 0/45 (0%) | 0/45 (0%) |
| LME636 | 0/29 (0%) | 1/29 (3.4%) | 13/29 (44.8%) |
| Dexamethasone | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| Posttreatment | 0/39 (0%) | 0/39 (0%) | 0/39 (0%) |
| Event | Pretreatment | LME636 | Dexamethasone | Posttreatment |
|---|---|---|---|---|
| Multiple sclerosisNervous system disorders | 0/45 | 1/29 | 0/10 | 0/39 |
| Event | Pretreatment | LME636 | Dexamethasone | Posttreatment |
|---|---|---|---|---|
| Anterior chamber cellEye disorders | 0/45 | 4/29 | 1/10 | 0/39 |
| Eye painEye disorders | 0/45 | 4/29 | 0/10 | 0/39 |
| Anterior chamber flareEye disorders | 0/45 | 3/29 | 0/10 | 0/39 |
| IridocyclitisEye disorders | 0/45 | 3/29 | 1/10 | 0/39 |
| Iris adhesionsEye disorders | 0/45 | 3/29 | 0/10 | 0/39 |
| PhotophobiaEye disorders | 0/45 | 3/29 | 0/10 | 0/39 |
| Ciliary muscle spasmEye disorders | 0/45 | 0/29 | 1/10 | 0/39 |
| IritisEye disorders | 0/45 | 0/29 | 1/10 | 0/39 |
| Lacrimation increasedEye disorders | 0/45 | 0/29 | 1/10 | 0/39 |
| Vitreous detachmentEye disorders | 0/45 | 0/29 | 1/10 | 0/39 |
This analysis population includes all randomized and treated subjects, as treated.
| Age, Continuous(years) | LME636 | Dexamethasone | Total |
|---|---|---|---|
| Mean | 54.1 ± 17.20 | 55.6 ± 16.02 | 54.5 ± 16.71 |
| Sex: Female, Male(Participants) | LME636 | Dexamethasone | Total |
|---|---|---|---|
| Female | 17 | 4 | 21 |
| Male | 12 | 6 | 18 |
No study locations are listed for this record.
Ran from Jul 2015 to primary completion in Mar 2016, 8 months.
Results were first posted in Aug 2017, 1 year 5 months after primary completion. A results delay was requested in Jan 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Licaminlimab